+1 (888) 794-0077
« Return

Virtual Tours Available Today

Explore our New Jersey facilities from wherever you are working, even the comfort of your own home.

Virtually tour our New Jersey facilities in Cranbury and Plainsboro to learn about our Bioanalytical and DMPK capabilities and instrumentation to support your drug discovery and development programs.

Let’s discuss how we can help you meet your goals!

Follow WuXi AppTec Laboratory Testing Division on LinkedIn for industry insights and program support.

For more information, please visit: https://labtesting.wuxiapptec.com/


As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”

Related Posts

From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling

From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling

Traditional toxicology testing requires complex schedules that align task workflows with finite resources such as technician time and access to laboratories and equipment. Managing interdependent parts of the process manually with spreadsheets or other basic tools, while easily accessible, is inflexible, cumbersome, and prone to error and inefficiency . Automated platforms and workflow systems have the potential to optimize—or revolutionize—all aspects of drug development and testing to enhance speed, accuracy, and coordination.

3 Therapeutic Considerations for the Future of Oligonucleotide Development

3 Therapeutic Considerations for the Future of Oligonucleotide Development

Oligonucleotide-based therapies are redefining how we approach diseases at their genetic origins. By modulating gene expression at the RNA level, these therapies offer an unprecedented degree of precision in drug development, making once-untreatable diseases targets for real solutions. This guide explores the therapeutic opportunities and innovations shaping oligonucleotide development and what it could mean for the future of patient care.